Try our Advanced Search for more refined results
Life Sciences
-
April 17, 2026
AI Health Co. Illegally Shared Genetic Data, Patients Say
A healthcare company powered by artificial intelligence violated Illinois' genetic privacy law and other consumer protection laws by compelling a genetic testing business it acquired to disclose patients' genetic information, which it then shared through data agreements with pharmaceutical giants such as Eli Lilly and AbbVie, a lawsuit in Illinois federal court says.
-
April 17, 2026
Judge Says Biotech Co. Can't Wipe Cancer Data, For Now
A Texas state judge signed a temporary restraining order on Friday that stops Bellicum Pharmaceuticals Inc. and the consulting firm helping it oversee its dissolution from deleting cell therapy data that the Houston-based MD Anderson Cancer Center says belongs to it.
-
April 17, 2026
Life Sciences Firm Says Ex-VP Took Trade Secrets To Rival
A Massachusetts life sciences startup says a former vice president who left the company last fall, purportedly to care for his ill wife, instead took trade secrets with him to a new job at a California rival.
-
April 17, 2026
Aramark Joins NJ Insulin Pricing Suits Against PBMs
Aramark Services Inc. joined multidistrict litigation accusing CVS and pharmacy benefit managers of colluding to inflate the price of insulin.
-
April 17, 2026
Polsinelli Sent Bogus Infringement Letters, Suits Say
National law firm Polsinelli PC was accused of sending letters to two medical device companies with meritless claims of patent infringement, the companies claimed in a pair of malpractice suits.
-
April 17, 2026
Latham Leads Kailera's $625M IPO In Obesity Drug Push
Obesity biotech Kailera Therapeutics made its public debut Friday, raising $625 million in an upsized initial public offering that represents one of the largest biotech IPOs in recent years.
-
April 17, 2026
Doc Says Texas Man Can't Sue Over Mailed Abortion Pills
A Texas man suing his ex-girlfriend's out-of-state doctor for prescribing mail-order abortion pills can't prove that the doctor caused the wrongful death of their unborn child, the doctor told a federal court, saying the case should be dismissed because he's not responsible for the woman's actions.
-
April 17, 2026
Fed. Circ. Reverses $18M Penile Implant Trade Secret Win
In a unanimous precedential decision, the Federal Circuit on Friday largely reversed a California jury's $18.3 million trade secret verdict over a penile implant, holding that the asserted secrets were already publicly disclosed or generally known and therefore not protectable.
-
April 16, 2026
Trump Taps Ret. Rear Admiral Schwartz As New CDC Chief
President Donald Trump on Thursday nominated Dr. Erica Schwartz, a retired rear admiral who served in the U.S. Coast Guard and as deputy surgeon general in the first Trump administration, to be the Centers for Disease Control and Prevention's next director.
-
April 16, 2026
Wis. Supreme Court Upholds Pabst Asbestos Verdict
The Wisconsin Supreme Court upheld a verdict in favor of the estate of a steamfitter exposed to asbestos through his work at a Pabst Brewing Co. brewery, saying Wednesday that the company still owed a duty of care to employees of independent contractors, but capped punitive damages to about $4.65 million.
-
April 16, 2026
Fed. Circ. Says Judge Wrongly Axed Teva's $177M Eli Lilly Win
The Federal Circuit ruled Thursday that a Massachusetts federal judge was wrong to overturn a $177 million jury verdict that Teva won against Eli Lilly & Co. on headache drug patents, finding that contrary to the judge's finding, the patents are not invalid.
-
April 16, 2026
IV Device Redesign Not Enough To Lift Ban, CBP Says
A U.S. medical device company's redesigned products used for intravenous drips are still barred from importation into the country, U.S. Customs and Border Protection said in an order released Thursday, with the agency unconvinced the new versions aren't still patent-infringing.
-
April 16, 2026
USPTO Ends COVID Patent Appeals Program
The U.S. Patent and Trademark Office has decided to end a program launched five years ago that aimed to prioritize and fast-track ex parte appeals of rejections on patent applications for inventions related to combating COVID-19.
-
April 16, 2026
Katten Partner Rejoins Epstein Becker In DC For 3rd Time
Epstein Becker Green LLP has rehired, for the third time, a healthcare transactional attorney who focuses his practice on guiding hospital systems, private equity-backed entities and professional practices on transactional matters and regulatory compliance.
-
April 15, 2026
Consumer Cases Drive Class Action Spike, Report Says
Federal class action filings spiked in 2025 after nearly a decade of relative stability, fueled by a surge in consumer protection lawsuits tied to data breaches, digital commerce and online accessibility claims, according to a new report from Lex Machina.
-
April 15, 2026
Amneal Trims But Can't Nix AGs' Drug Price-Fixing Suit
There is enough evidence from which a jury could conclude that Amneal Pharmaceuticals participated in a conspiracy to fix the price of an epilepsy medication, but not enough to show it participated in the overarching antitrust conspiracy alleged by dozens of state attorneys general, a Connecticut federal judge ruled Wednesday.
-
April 15, 2026
Drugmaker Aquestive's Brass Sued Over FDA Setback
Executives and directors of pharmaceutical company Aquestive Therapeutics Inc. were hit with a shareholder's derivative suit Wednesday accusing them of ignoring deficiencies in a research study for Aquestive's allergic reaction treatment, which eventually prompted the U.S. Food and Drug Administration to reject the company's new drug application.
-
April 15, 2026
Ex-DOJ Antitrust Atty On Google Case Joins Wilson Sonsini
A lead attorney on the U.S. Department of Justice Antitrust Division's monopolization cases against Google LLC who left the agency last week joined Wilson Sonsini Goodrich & Rosati PC in Washington, D.C., on Wednesday as a partner.
-
April 15, 2026
Squires Passes On 10 Patent Challenges, Takes On 2 Others
The newest bulk order from U.S. Patent and Trademark Office Director John Squires has rejected 10 petitions for America Invents Act patent reviews while granting a couple others, including a Google challenge to a patent owned by Headwater Research LLC.
-
April 15, 2026
NC Judge Won't Undo $4M Philips Copyright Verdict
A North Carolina federal judge has refused to erase a $4 million jury verdict against independent service organization Transtate Equipment Co. for violations of the Digital Millennium Copyright Act, saying trial evidence provided a "firm basis" to support the jury's statutory damages award.
-
April 15, 2026
Willkie Adds O'Melveny Litigator To Los Angeles Office
Willkie Farr & Gallagher LLP expanded its Los Angeles office with the recent addition of a litigator who moved her practice after nearly 15 years with O'Melveny & Myers LLP.
-
April 15, 2026
Biopharma Co. Says Ex-Worker Used Files To Build AI Rival
A biopharmaceutical consulting firm's ex-contractor illegally downloaded thousands of proprietary internal files and emails that he then used to launch a rival company powered by artificial intelligence, the firm claimed in a lawsuit, alleging that the former contractor violated federal trade secrets law.
-
April 14, 2026
Armistice Capital Used COVID To Juice Vaxart Stock, Jury Told
Hedge fund Armistice Capital and two of its executives exploited the COVID-19 pandemic to issue press releases that falsely inflated their controlling share in pharmaceutical company Vaxart, then dumped the shares for $250 million before the bottom fell out, investors told a California federal jury at the start of trial Tuesday.
-
April 14, 2026
4th Circ. Revives Pharma Bid To Block Maryland's 340B Law
A split Fourth Circuit panel on Tuesday tossed a Maryland district court's order denying a preliminary injunction to pharmaceutical manufacturers that have challenged a state law addressing drug delivery in the federal 340B discount program, pointing to its recent ruling that West Virginia's similar statute is likely preempted.
-
April 14, 2026
States Denied Time For Talks To Settle Drug Price-Fixing Suit
A Connecticut federal judge Tuesday denied a request by dozens of U.S. states to freeze their antitrust case against generic-drug manufacturers, a pause the states argued would allow the parties to focus on settlement talks rather than pending discovery and motion deadlines.
Editor's Picks
-
Supreme Court Will Tackle Patent Enablement In Amgen Case
The U.S. Supreme Court on Friday agreed to review Section 112 of the Patent Act for the second time in the law's history, accepting Amgen's request to consider how much a patent must disclose in order to meet enablement requirements.
-
A Circuit-By-Circuit Guide To FCA Suits After High Court Snub
The U.S. Supreme Court's refusal to resolve one of the False Claims Act's most consequential controversies leaves circuit courts deeply divided over whistleblower pleading obligations in ways that will reverberate nationwide, attorneys say. Here, Law360 explores each circuit's approach and scenarios that might finally trigger high court intervention.
-
Inside The Collapse Of A Pioneering Opioid Case For DOJ
The U.S. Department of Justice launched a "terribly flawed" criminal case against a drug distributor and several individuals amid pressure to alleviate Appalachia's opioid crisis, and a newly confirmed U.S. attorney displayed "courage and guts" by ending the case last month, defense counsel told Law360 in an expansive interview.
Expert Analysis
-
2 Discovery Rulings Break With Heppner On AI Privilege Issue
While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.
-
Series
Isshin-Ryu Karate Makes Me A Better Lawyer
My involvement in martial arts, specifically Isshin-ryu, which has principles rooted in the eight codes of karate, has been one of the most foundational in the development of my personality, and particularly my approach to challenges — including in my practice of law, says Kaitlyn Stone at Barnes & Thornburg.
-
Microplastics On Water Contaminant List Could Spur Claims
The U.S. Environmental Protection Agency's proposal to include microplastics in its draft sixth Contaminant Candidate List under the Safe Drinking Water Act could influence consumer fraud claims and enforcement by state attorneys general, as well as claims against manufacturers from entities facing regulatory compliance costs, says Arie Feltman-Frank at Jenner & Block.
-
USPTO's AI Search Pilot May Reshape Patent Filing Strategy
The U.S. Patent and Trademark Office's new artificial intelligence search pilot aims to introduce earlier visibility into the prior art landscape, potentially influencing patent filing considerations and shifting the role of counsel to an earlier stage of the prosecution process, say attorneys at Foley & Lardner.
-
Peptide Policy Is Shifting Toward Sanctioned Compounding
The policy landscape for peptides is undergoing a significant shift under the Trump administration, moving toward a complex system of verified compounding and complementary enforcement that will likely bring peptides firmly back into the sphere of legitimate consumer products, say attorneys at Sheppard.
-
Keys To Building Defensible Psychedelic Therapy Programs
Given the rapidly evolving legal environment for psychedelic therapies and heightened liability and compliance risks facing providers, meticulous documentation, robust risk management protocols, and proactive engagement with professional organizations and insurers are essential strategies, say Kimberly Chew at Husch Blackwell and L. Alison McInnes at Mindful Health Solutions.
-
Opinion
State Bars Need To Get Specific About AI Confidentiality
Lawyers need to put actual client information into artificial intelligence tools to get their full value, but they cannot confidently do so until state bars offer clear, formal authority on which plan tiers of the three most popular generative AI tools are safe to use when sharing specific client details, says attorney Nick Berk.
-
Series
Alpine Skiing Makes Me A Better Lawyer
Skiing has shaped habits I rely on daily as an attorney — focus, resilience and the ability to remain steady when circumstances shift rapidly — and influences the way I approach legal strategy, client counseling and teamwork, says Isaku Begert at Marshall Gerstein.
-
FDA Guidance May Move Goalposts For Form 483 Responses
New draft guidance from the U.S. Food and Drug Administration provides formal insight on how drug manufacturers are expected to respond to Form 483s, raising some concerns about the agency's timelines and expectations, say attorneys at Cooley.
-
2 Strands Of Patent Law In High Court's 'Skinny Label' Case
Amarin v. Hikma, which is set for oral argument in the U.S. Supreme Court this month, highlights the distinction between two different strands of intellectual property law — analogizing a patent to either a property deed or a home, says Jonas McDavit at Spencer West.
-
Why MDLs Slow Down — And How To Speed Them Up
Multidistrict litigation has become central to mass tort practice, but as MDLs grow in size and complexity, so do delays and costs — so tools like the new federal rule governing MDLs, targeted use of special masters and strategically deployed Lone Pine orders are more essential than ever, say attorneys at Ice Miller.
-
A Check-Up On HHS' Push To Implement AI Infrastructure
The U.S. Department of Health and Human Services has made some headway in its efforts to implement artificial intelligence across its agencies, but will have to overcome a number of near-term tests in order to be successful, says Theodore Thompson at Stinson.
-
What A Court Doc Audit Reveals About Erroneous Filings
My audit of 1,522 court documents from last month found that over 95% contained at least one verifiable error, with fewer than 1% showing clear indicators of artificial intelligence use — highlighting above all else that lawyers may want to focus most on strengthening their review processes, says Elliott Ash at ETH Zurich.
-
Series
Mich. Banking Brief: All The Notable Legal Updates In Q1
Michigan's financial services sector saw several significant developments in 2026's first quarter, including the state Department of Insurance and Financial Services' issuance of a bulletin on the use of artificial intelligence and the Michigan House's introduction of a bill based on the Model Money Transmission Modernization Act, say attorneys at Dykema.
-
The Road Ahead For Drug Development In The US
Against the backdrop of drug manufacturers potentially looking to move development efforts overseas, the U.S. Food and Drug Administration's latest guidance on new approach methodologies signals the FDA is likely to be receptive to industry innovation that makes U.S.-based drug development faster or less expensive, creating opportunities and compliance risks for tech companies, say attorneys at Morgan Lewis.